TNF Receptor Type II as an Emerging Drug Target for the Treatment of Cancer, Autoimmune Diseases, and Graft-Versus-Host Disease: Current Perspectives and In Silico Search for Small Molecule Binders

Overview of attention for article published in Frontiers in immunology, June 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter: 4 X users
patent: 3 patents

f1000: 1 research highlight platform

Citations

dimensions_citation: 18 Dimensions

Readers on

mendeley: 45 Mendeley

Summary X Patents Research highlights Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 34,023 followers.

RT @FrontImmunol: TNF Receptor Type II as an Emerging Drug Target for the Treatment of Cancer, Autoimmune Diseases, and Graft-Versus-Host D…

25 Jul 2018

Reply Repost Favourite

RT @FrontImmunol: TNF Receptor Type II as an Emerging Drug Target for the Treatment of Cancer, Autoimmune Diseases, and Graft-Versus-Host D…

24 Jul 2018

Reply Repost Favourite

RT @FrontImmunol: TNF Receptor Type II as an Emerging Drug Target for the Treatment of Cancer, Autoimmune Diseases, and Graft-Versus-Host D…

24 Jul 2018

Reply Repost Favourite

TNF Receptor Type II as an Emerging Drug Target for the Treatment of Cancer, Autoimmune Diseases, and Graft-Versus-Host Disease: Current Perspectives and In Silico Search for Small Molecule Binders: Faraz Shaikh, Jiang He, Pratiti Bhadra, Xin Chen,… https:

24 Jul 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.